Xin Wu

Dr. Xin Wu

Department of Pharmacy, Fujian University of Traditional Chinese Medicine, cShanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
JQJiecheng Qian
Jiecheng Qian
YGYankun Guo
Yankun Guo
YXYoufa Xu
Youfa Xu
XWXinyu Wang
Xinyu Wang
XWXin Wu
Xin Wu
XWXin Wu
Xin Wu

1 January 2021 in Drug Delivery
Verified
Journal Article
Open access
HCHang Chen
Hang Chen
SHSifan Huang
Sifan Huang
HWHeyi Wang
Heyi Wang
XCXinmei Chen
Xinmei Chen
HZHaiyan Zhang
Haiyan Zhang
XWXin Wu
Xin Wu
Combination of the prodrug technique with an albumin nano drug-loaded system is a novel promising approach for cancer treatment. However, the long-lasting and far-reaching challenge for the treatme...

1 May 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YHYongjie Huang
Yongjie Huang
TWTiansi Wang
Tiansi Wang
JYJiefen Yang
Jiefen Yang
XWXin Wu
Xin Wu
WFWei Fan
Wei Fan
XWXin Wu
Xin Wu
Liver cancer remains a global health challenge with a projected incidence of over one million cases by 2025. Hepatocellular carcinoma (HCC) is a common primary liver cancer, accounting for about 90% of all liver cancer cases. The tumor microenvironment (TME) is the internal and external environment for tumor development, which plays an important role in tumorigenesis, immune escape and treatment resistance. Knowing that TME is a unique setting for HCC tumorigenesis, exploration of strategies to modulate TME has attracted increasing attention. Among them, the use of nano-delivery systems to deliver therapeutic agents to regulate TME components has shown great potential. TME-modulating nanoparticles have the advantages of protecting therapeutic agents from degradation, enhancing the ability of targeting HCC and reducing systemic toxicity. In this article, we summarize the TME components associated with HCC, including cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), endothelial cells and immune cells, discuss their impact on the HCC progression, and highlight recent studies on nano-delivery systems that modulate these components. Finally, we also discuss opportunities and challenges in this field.

5 April 2022 in Drug Delivery
Verified
Journal Article
Open access
SHSifan Huang
Sifan Huang
XWXinyu Wang
Xinyu Wang
MLMengmeng Liu
Mengmeng Liu
ZLZhizhe Lin
Zhizhe Lin
WGWenqian Gu
Wenqian Gu
XWXin Wu
Xin Wu
Sodium aescinate (SA) is often used for intravenous (IV) injection owing to its anti-inflammatory, anti-exudative, increasing venous tension, improving blood circulation and reducing swelling activities. However, the clinical application of SA is limited by strong irritation, short half-life and low bioavailability. To overcome these defects, we intended to modify SA by encapsualing it with liposomes . SA was mixed with a proper amount of phospholipid and lyophilized to prepare the liposome of sodium aescinate for injection (SA-Lip-I). Its physical properties, cumulative release and dilution stability were evaluated in vitro. Its pharmacodynamic characteristics were evaluated. Safety of SA-Lip-I was evaluated in terms of hemolysis, IV irritation and acute toxicity. The mean particle size of SA-Lip-I was 117.33±0.95 nm, polydispersity index (PDI) was 0.140±0.017, Zeta potential was -30.34±0.23 mv, The cumulative release of SA-Lip at 12 h was more than 80%, which met the release requirements of nanoparticles. SA-Lip-I was well stable in the four mediators and met the clinical medication requirements. In addition, SA-Lip-I had better efficacy than the SA-I and has a significant difference. Furthermore, SA-Lip-I did not induce hemolysis at 37°C, and produced by far milder venous irritation as compared with SA-I. In addition, LD50 of SA-Lip-I was 2.12 fold that of the commercial SA-I, with no obvious side effects.The modified SA-Lip-I is a promising preparation which can reduce the irritation and toxic side effects, improve the treatment effect to a certain extent, but greatly alleviate pain of the patient during treatment, achieving the optimal curative effect.

18 September 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
JYJiefen Yang
Jiefen Yang
XSXiongxi Shi
Xiongxi Shi
YKYanting Kuang
Yanting Kuang
RWRuting Wei
Ruting Wei
LFLanni Feng
Lanni Feng
XWXin Wu
Xin Wu

11 March 2024 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YKYanting Kuang
Yanting Kuang
ZLZhaokai Li
Zhaokai Li
HCHang Chen
Hang Chen
XWXinyu Wang
Xinyu Wang
YWYan Wen
Yan Wen
XWXin Wu
Xin Wu